Dr. Jiang is a prolific inventor and a co-founder of Cytek Biosciences. As the CEO and Chairman of the Board, Dr. Jiang has led the company through four rounds of financing for a total of $200M raised, grown the company to multi-continents and achieved an average growth rate exceeding 100% over the life of the company.
Prior to Cytek Biosciences, Dr. Jiang served as CTO at Cosemi Technologies Inc. and JDSU Transmission Module BU. He received a PhD in Electrical Engineering from the University of California, Santa Barbara, a MS in Optics and a BS in Physics from Fudan University in Shanghai, China.
Over his career, he has contributed to 100 US patents, published more than 50 peer reviewed journal and conference papers, and wrote 5 book chapters. He has been awarded the Motorola Master Innovator Award and JDSU Inventor of the Year.
Jack Ball is CEO and a board member at Solulink Inc. He is President of Tyball Associates, LLC. In addition, he serves on the board of directors of Aquaro Histology, Carterra, Celsee Diagnostics, Cytek Biosciences Inc., NanoCellect Inc. and Swift Bioscience. Most recently he was CCO at Accuri Cytometers, which was sold to Becton Dickinson in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, and has also served as CCO for Molecular Probes, Inc.
Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President for North Amercia.
Dr. Yan is a co-founder of Cytek Biosciences with over 25 years of R&D experience in leadership and innovation. As CTO of Cytek, Ming leads the development team (including hardware, software, reagents, and applications), and with the team, drives the advancement of the Cytek Platform.
Prior to Cytek, Ming worked in the biomedical instruments industry and integrated photonics at AT&T Bell laboratories, Livermore national laboratories, Neophotonics and BD Biosciences. Ming is one of the thought-leaders in flow cytometry instrumentation and standardization. He received his Ph.D in Electrical Engineering and MS in Physics from City University of New York, BS in Physics from Fudan University.
Dr. Yan has published over 40 research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.
Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He currently manages over US$ 4.5 billion. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer.
Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. He has extensive technical and managerial experiences in computer, communication and data networking industries.
Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.
Gisele Dion has served as a member of our board of directors since March 2021. Ms. Dion is the Senior Advisor to the Chief Financial Officer of Takeda Pharmaceutical Ltd., a pharmaceutical company. Previously, she served as the Senior Vice President, Chief Accounting Officer and Corporate Controller at Takeda Pharmaceutical Ltd. from January 2019 to March 2021.
Prior to that, Ms. Dion was the Senior Vice President, Chief Accounting Officer and Corporate Controller at Shire Pharmaceuticals LLC, a biopharmaceutical company, from January 2016 to January 2019. From 2007 to January 2016, she served as Corporate Controller and Senior Director of Technical Accounting of Biogen Inc., a biotechnology company.
Ms. Dion received a B.S. in Accounting and Management Information Systems from Fairfield University.
Tess Cameron has served as a member of our board of directors since April 2021. Ms. Cameron is the Principal, Strategic Finance at RA Capital Management, LP. From January 2018 to June 2020, Ms. Cameron served as the Head of Finance of Foghorn Therapeutics, Inc., a pharmaceutical company. From January 2017 to January 2018, Ms. Cameron served as the Director, Financial and Business Planning at WAVE Life Sciences Ltd., a biotechnology company.
Prior to that Ms. Cameron was the Associate Director, Finance Business Planning and Senior Finance Manager at Biogen Inc., a biotechnology company and worked at McKinsey & Company, a management consulting company.
Ms. Cameron holds a B.A. in Economics and Peace Conflict Studies from Victoria University, University of Toronto and graduated from the Mini-MBA program at the Tuck School of Business, Dartmouth College.